+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07851103

Testing Doses of BI 3968621 Alone or With Ezabenlimab in Adults With Advanced Solid Tumors to Assess Safety and Tumor Response

Led by Boehringer Ingelheim · Updated on 2026-10-28

90

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. The trial aims to identify the highest and most suitable dose of the drug BI 3968621, given alone or with ezabenlimab, that patients can tolerate. This is a first-in-human phase 1 study assessing safety, tolerability, and preliminary anti-tumor activity of these medicines in people with advanced cancer. The study has three parts Part A, Part A2, and Part B. Participants receive BI 3968621 alone or in combination with ezabenlimab depending on the study part. BI 3968621 is taken daily as tablets, while ezabenlimab is given as an infusion into a vein every three weeks. Part A finds the suitable dose of BI 3968621 alone, Part A2 evaluates tumor response in kidney cancer at specific doses, and Part B assesses tolerability of the combination treatment. Participants may receive treatment for up to two years if they benefit and tolerate it. During the study, participants visit the study site regularly according to their response and tolerance. Researchers monitor severe health problems occurring within three weeks after the first treatment. They also assess participants overall health, record side effects, take blood samples, and evaluate how the cancer responds to the treatments. The main outcome measures include dose-limiting toxicities during the first treatment cycle and objective tumor response up to two years.

CONDITIONS

Brief Title

A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here